Valeant Pharmaceuticals International Settles Suit with Kali Laboratories, Inc. on Diastat Generic Challenge

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Valeant Pharmaceuticals International (NYSE: VRX) today announced that it has settled its lawsuit with Kali Laboratories, Inc. for patent infringement on Diastat®, the only FDA-approved at-home acute treatment for break-through epileptic seizures. Under the terms of the settlement, the companies reached an agreement in principle that would allow Kali to introduce a generic version of Diastat and Diastat® AcuDial™ no earlier than September 2010. Other terms of the settlement were not disclosed.